Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Genetic Mosaicism in Calmodulinopathy.

Wren LM, Jiménez-Jáimez J, Al-Ghamdi S, Al-Aama JY, Bdeir A, Al-Hassnan ZN, Kuan JL, Foo RY, Potet F, Johnson CN, Aziz MC, Carvill GL, Kaski JP, Crotti L, Perin F, Monserrat L, Burridge PW, Schwartz PJ, Chazin WJ, Bhuiyan ZA, George AL Jr.

Circ Genom Precis Med. 2019 Sep;12(9):375-385. doi: 10.1161/CIRCGEN.119.002581. Epub 2019 Aug 27.

PMID:
31454269
2.

Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease.

Magdy T, Burridge PW.

Cell Stem Cell. 2019 Feb 7;24(2):203-205. doi: 10.1016/j.stem.2019.01.008.

PMID:
30735646
3.

hiPSCs in cardio-oncology: deciphering the genomics.

Pinheiro EA, Fetterman KA, Burridge PW.

Cardiovasc Res. 2019 Apr 15;115(5):935-948. doi: 10.1093/cvr/cvz018.

PMID:
30689737
4.

Are These Cardiomyocytes? Protocol Development Reveals Impact of Sample Preparation on the Accuracy of Identifying Cardiomyocytes by Flow Cytometry.

Waas M, Weerasekera R, Kropp EM, Romero-Tejeda M, Poon EN, Boheler KR, Burridge PW, Gundry RL.

Stem Cell Reports. 2019 Feb 12;12(2):395-410. doi: 10.1016/j.stemcr.2018.12.016. Epub 2019 Jan 24.

5.

Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.

Sharma A, McKeithan WL, Serrano R, Kitani T, Burridge PW, Del Álamo JC, Mercola M, Wu JC.

Nat Protoc. 2018 Dec;13(12):3018-3041. doi: 10.1038/s41596-018-0076-8.

PMID:
30413796
6.

Doxorubicin induces caspase-mediated proteolysis of KV7.1.

Strigli A, Raab C, Hessler S, Huth T, Schuldt AJT, Alzheimer C, Friedrich T, Burridge PW, Luedde M, Schwake M.

Commun Biol. 2018 Sep 28;1:155. doi: 10.1038/s42003-018-0162-z. eCollection 2018.

7.

Stage-specific Effects of Bioactive Lipids on Human iPSC Cardiac Differentiation and Cardiomyocyte Proliferation.

Sharma A, Zhang Y, Buikema JW, Serpooshan V, Chirikian O, Kosaric N, Churko JM, Dzilic E, Shieh A, Burridge PW, Wu JC, Wu SM.

Sci Rep. 2018 Apr 26;8(1):6618. doi: 10.1038/s41598-018-24954-3.

8.

The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity.

Magdy T, Burridge PW.

Pharmacogenomics. 2018 Jan;19(2):79-82. doi: 10.2217/pgs-2017-0177. Epub 2017 Dec 4. No abstract available.

9.

Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling.

Abilez OJ, Tzatzalos E, Yang H, Zhao MT, Jung G, Zöllner AM, Tiburcy M, Riegler J, Matsa E, Shukla P, Zhuge Y, Chour T, Chen VC, Burridge PW, Karakikes I, Kuhl E, Bernstein D, Couture LA, Gold JD, Zimmermann WH, Wu JC.

Stem Cells. 2018 Feb;36(2):265-277. doi: 10.1002/stem.2732. Epub 2017 Nov 13.

10.

Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.

Magdy T, Schuldt AJT, Wu JC, Bernstein D, Burridge PW.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:83-103. doi: 10.1146/annurev-pharmtox-010617-053110. Epub 2017 Oct 6. Review.

PMID:
28992430
11.

Acute CD47 Blockade During Ischemic Myocardial Reperfusion Enhances Phagocytosis-Associated Cardiac Repair.

Zhang S, Yeap XY, DeBerge M, Naresh NK, Wang K, Jiang Z, Wilcox JE, White SM, Morrow JP, Burridge PW, Procissi D, Scott EA, Frazier W, Thorp EB.

JACC Basic Transl Sci. 2017 Aug;2(4):386-397. doi: 10.1016/j.jacbts.2017.03.013.

12.

Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.

Flevaris P, Khan SS, Eren M, Schuldt AJT, Shah SJ, Lee DC, Gupta S, Shapiro AD, Burridge PW, Ghosh AK, Vaughan DE.

Circulation. 2017 Aug 15;136(7):664-679. doi: 10.1161/CIRCULATIONAHA.117.028145. Epub 2017 Jun 6.

13.

Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2.

Yang X, Park SH, Chang HC, Shapiro JS, Vassilopoulos A, Sawicki KT, Chen C, Shang M, Burridge PW, Epting CL, Wilsbacher LD, Jenkitkasemwong S, Knutson M, Gius D, Ardehali H.

J Clin Invest. 2017 Apr 3;127(4):1505-1516. doi: 10.1172/JCI88574. Epub 2017 Mar 13.

14.

Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease.

Lin ZC, McGuire AF, Burridge PW, Matsa E, Lou HY, Wu JC, Cui B.

Microsyst Nanoeng. 2017 Mar 13;3:16080. doi: 10.1038/micronano.2016.80. eCollection 2017.

15.

High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.

Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC.

Sci Transl Med. 2017 Feb 15;9(377). pii: eaaf2584. doi: 10.1126/scitranslmed.aaf2584.

16.

Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Magdy T, Burmeister BT, Burridge PW.

Pharmacol Ther. 2016 Dec;168:113-125. doi: 10.1016/j.pharmthera.2016.09.009. Epub 2016 Sep 5. Review.

17.

Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.

Matsa E, Burridge PW, Yu KH, Ahrens JH, Termglinchan V, Wu H, Liu C, Shukla P, Sayed N, Churko JM, Shao N, Woo NA, Chao AS, Gold JD, Karakikes I, Snyder MP, Wu JC.

Cell Stem Cell. 2016 Sep 1;19(3):311-25. doi: 10.1016/j.stem.2016.07.006. Epub 2016 Aug 18.

18.

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, Holmström A, Chang AC, Coronado MJ, Ebert AD, Knowles JW, Telli ML, Witteles RM, Blau HM, Bernstein D, Altman RB, Wu JC.

Nat Med. 2016 May;22(5):547-56. doi: 10.1038/nm.4087. Epub 2016 Apr 18.

19.

Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine.

Burridge PW, Sharma A, Wu JC.

Annu Rev Genet. 2015;49:461-84. doi: 10.1146/annurev-genet-112414-054911. Review.

20.

Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells.

Burridge PW, Holmström A, Wu JC.

Curr Protoc Hum Genet. 2015 Oct 6;87:21.3.1-15. doi: 10.1002/0471142905.hg2103s87.

21.
22.

Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Burridge PW, Diecke S, Matsa E, Sharma A, Wu H, Wu JC.

Methods Mol Biol. 2016;1353:119-30. doi: 10.1007/7651_2015_196.

23.

Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes.

Burridge PW, Metzler SA, Nakayama KH, Abilez OJ, Simmons CS, Bruce MA, Matsuura Y, Kim P, Wu JC, Butte M, Huang NF, Yang PC.

Am J Transl Res. 2014 Nov 22;6(6):724-35. eCollection 2014.

24.

Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency.

Diecke S, Lu J, Lee J, Termglinchan V, Kooreman NG, Burridge PW, Ebert AD, Churko JM, Sharma A, Kay MA, Wu JC.

Sci Rep. 2015 Jan 28;5:8081. doi: 10.1038/srep08081.

25.

Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.

Gu M, Mordwinkin NM, Kooreman NG, Lee J, Wu H, Hu S, Churko JM, Diecke S, Burridge PW, He C, Barron FE, Ong SG, Gold JD, Wu JC.

Eur Heart J. 2015 Apr 1;36(13):806-16. doi: 10.1093/eurheartj/ehu411. Epub 2014 Nov 2.

26.

High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry.

Bhattacharya S, Burridge PW, Kropp EM, Chuppa SL, Kwok WM, Wu JC, Boheler KR, Gundry RL.

J Vis Exp. 2014 Sep 23;(91):52010. doi: 10.3791/52010.

27.

Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system.

Ebert AD, Kodo K, Liang P, Wu H, Huber BC, Riegler J, Churko J, Lee J, de Almeida P, Lan F, Diecke S, Burridge PW, Gold JD, Mochly-Rosen D, Wu JC.

Sci Transl Med. 2014 Sep 24;6(255):255ra130. doi: 10.1126/scitranslmed.3009027.

28.

A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets.

Boheler KR, Bhattacharya S, Kropp EM, Chuppa S, Riordon DR, Bausch-Fluck D, Burridge PW, Wu JC, Wersto RP, Chan GC, Rao S, Wollscheid B, Gundry RL.

Stem Cell Reports. 2014 Jun 6;3(1):185-203. doi: 10.1016/j.stemcr.2014.05.002. eCollection 2014 Jul 8.

29.

Induced pluripotent stem cells from familial Alzheimer's disease patients differentiate into mature neurons with amyloidogenic properties.

Mahairaki V, Ryu J, Peters A, Chang Q, Li T, Park TS, Burridge PW, Talbot CC Jr, Asnaghi L, Martin LJ, Zambidis ET, Koliatsos VE.

Stem Cells Dev. 2014 Dec 15;23(24):2996-3010. doi: 10.1089/scd.2013.0511.

30.

Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform.

Sharma A, Marceau C, Hamaguchi R, Burridge PW, Rajarajan K, Churko JM, Wu H, Sallam KI, Matsa E, Sturzu AC, Che Y, Ebert A, Diecke S, Liang P, Red-Horse K, Carette JE, Wu SM, Wu JC.

Circ Res. 2014 Aug 29;115(6):556-66. doi: 10.1161/CIRCRESAHA.115.303810. Epub 2014 Jul 11.

31.

Chemically defined generation of human cardiomyocytes.

Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC.

Nat Methods. 2014 Aug;11(8):855-60. doi: 10.1038/nmeth.2999. Epub 2014 Jun 15.

32.

Human stem cells for modeling heart disease and for drug discovery.

Matsa E, Burridge PW, Wu JC.

Sci Transl Med. 2014 Jun 4;6(239):239ps6. doi: 10.1126/scitranslmed.3008921. Review.

33.

Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.

Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Sharma A, Burridge PW, Patlolla B, Lee AS, Wu H, Beygui RE, Wu SM, Robbins RC, Bers DM, Wu JC.

Circulation. 2013 Sep 10;128(11 Suppl 1):S3-13. doi: 10.1161/CIRCULATIONAHA.112.000570. Erratum in: Circulation. 2014 Apr 15;129(15):e452.

34.
35.

Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes.

Burridge PW, Zambidis ET.

Methods Mol Biol. 2013;997:149-61. doi: 10.1007/978-1-62703-348-0_12.

PMID:
23546754
36.

A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.

Mordwinkin NM, Burridge PW, Wu JC.

J Cardiovasc Transl Res. 2013 Feb;6(1):22-30. doi: 10.1007/s12265-012-9423-2. Epub 2012 Nov 15. Review.

37.

Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model.

Thompson SA, Burridge PW, Lipke EA, Shamblott M, Zambidis ET, Tung L.

J Mol Cell Cardiol. 2012 Jul;53(1):15-23. doi: 10.1016/j.yjmcc.2012.01.023. Epub 2012 Feb 10.

38.

Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming.

Burridge PW, Keller G, Gold JD, Wu JC.

Cell Stem Cell. 2012 Jan 6;10(1):16-28. doi: 10.1016/j.stem.2011.12.013.

39.

Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology.

Gundry RL, Burridge PW, Boheler KR.

Proteomics. 2011 Oct;11(20):3947-61. doi: 10.1002/pmic.201100100. Epub 2011 Sep 8. Review.

40.

A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.

Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, Peters A, Mahairaki V, Koliatsos VE, Tung L, Zambidis ET.

PLoS One. 2011 Apr 8;6(4):e18293. doi: 10.1371/journal.pone.0018293.

41.

Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells.

Peters A, Burridge PW, Pryzhkova MV, Levine MA, Park TS, Roxbury C, Yuan X, Péault B, Zambidis ET.

Int J Dev Biol. 2010;54(6-7):965-90. doi: 10.1387/ijdb.093043ap. Review.

42.

Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability.

Burridge PW, Anderson D, Priddle H, Barbadillo Muñoz MD, Chamberlain S, Allegrucci C, Young LE, Denning C.

Stem Cells. 2007 Apr;25(4):929-38. Epub 2006 Dec 21.

43.

Hematopoiesis from human embryonic stem cells: overcoming the immune barrier in stem cell therapies.

Priddle H, Jones DR, Burridge PW, Patient R.

Stem Cells. 2006 Apr;24(4):815-24. Epub 2005 Nov 23. Review.

44.

Technical aspects of islet preparation and transplantation.

Lakey JR, Burridge PW, Shapiro AM.

Transpl Int. 2003 Sep;16(9):613-32. Epub 2003 Aug 19. Review.

PMID:
12928769
45.

Future trends in clinical islet transplantation.

Burridge PW, Shapiro AM, Ryan EA, Lakey JR.

Transplant Proc. 2002 Dec;34(8):3347-8. No abstract available.

PMID:
12493469
46.

A physical map of the mouse genome.

Gregory SG, Sekhon M, Schein J, Zhao S, Osoegawa K, Scott CE, Evans RS, Burridge PW, Cox TV, Fox CA, Hutton RD, Mullenger IR, Phillips KJ, Smith J, Stalker J, Threadgold GJ, Birney E, Wylie K, Chinwalla A, Wallis J, Hillier L, Carter J, Gaige T, Jaeger S, Kremitzki C, Layman D, Maas J, McGrane R, Mead K, Walker R, Jones S, Smith M, Asano J, Bosdet I, Chan S, Chittaranjan S, Chiu R, Fjell C, Fuhrmann D, Girn N, Gray C, Guin R, Hsiao L, Krzywinski M, Kutsche R, Lee SS, Mathewson C, McLeavy C, Messervier S, Ness S, Pandoh P, Prabhu AL, Saeedi P, Smailus D, Spence L, Stott J, Taylor S, Terpstra W, Tsai M, Vardy J, Wye N, Yang G, Shatsman S, Ayodeji B, Geer K, Tsegaye G, Shvartsbeyn A, Gebregeorgis E, Krol M, Russell D, Overton L, Malek JA, Holmes M, Heaney M, Shetty J, Feldblyum T, Nierman WC, Catanese JJ, Hubbard T, Waterston RH, Rogers J, de Jong PJ, Fraser CM, Marra M, McPherson JD, Bentley DR.

Nature. 2002 Aug 15;418(6899):743-50. Epub 2002 Aug 4.

PMID:
12181558
47.

Evaluation of a computer-based clinical reference library in an ICU.

Burridge PW, Skakun EN, King EG.

Crit Care Med. 1985 Sep;13(9):763-6.

PMID:
4028773
48.

Relationships among purine nucleoside metabolism, adenosine triphosphate catabolism, and glycolysis in human erythrocytes.

Henderson JF, Zombor G, Burridge PW, Barankiewicz G, Smith CM.

Can J Biochem. 1979 Jun;57(6):873-8.

PMID:
476524
49.
50.

Purine metabolism in Saccharomyces cerevisiae.

Burridge PW, Woods RA, Henderson JF.

Can J Biochem. 1977 Sep;55(9):935-41.

PMID:
332289

Supplemental Content

Loading ...
Support Center